Endogenous production of nitric oxide contributes to proliferation effect of vascular endothelial growth factor-induced malignant melanoma cell

Clinical and Experimental Dermatology

Volumn 31, Issue 1, 2006, Pages 94-99

  Tao, J ^a   Tu, Y T ^a   Li, J W ^a   Feng, A P ^a   Huang, C Z ^a   Wu, Y ^a   Shen, G X ^b  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENZYME INHIBITOR; INDUCIBLE NITRIC OXIDE SYNTHASE; MESSENGER RNA; N(G) NITROARGININE METHYL ESTER; NEURONAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE; NITRITE; RNA; VASCULOTROPIN;

ARTICLE; BIOSYNTHESIS; CELL DIVISION; DRUG EFFECT; EXPERIMENTAL MELANOMA; GENETIC TRANSFECTION; HUMAN; PATHOPHYSIOLOGY; PHYSIOLOGY; PLASMID; TUMOR CELL LINE;

CELL DIVISION; CELL LINE, TUMOR; ENZYME INHIBITORS; HUMANS; MELANOMA, EXPERIMENTAL; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE I; NITRIC OXIDE SYNTHASE TYPE II; NITRIC OXIDE SYNTHASE TYPE III; NITRITES; PLASMIDS; RNA, MESSENGER; RNA, NEOPLASM; TRANSFECTION; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 33646091103     PISSN: 03076938     EISSN: 13652230     Source Type: Journal    
DOI: 10.1111/j.1365-2230.2005.01922.x     Document Type: Article

References (22)

1. Ferrara N, Davis-Smyth T. The biology of vascular endot-helial growth factor. Endocr Rev 1997; 18: 4-25.
2. De Vries C, Escobedo JA, Ueno H et al. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 1992; 255: 989-91.
3. Quinn TP, Peters KG, De Vries C et al. Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium. Proc Natl Acad Sci USA 1993; 90: 7533-7.
4. Waltenberger J, Claesson-Welsh L, Siegbahn A et al. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem 1994; 269: 26988-95.
5. Liu B, Earl HM, Baban D et al. Melanoma cell lines express VEGF receptor KDR and respond to exogenously added VEGF. Biochem Biophys Res Commun 1995; 217: 721-7.
6. Masood R, Kundra A, Zhu S et al. Malignant mesothelioma growth inhibition by agents that target the VEGF and VEGF-C autocrine loops. Int J Cancer 2003; 104: 603-10.
7. Cobbs CS, Brenman JE, Aldape KD et al. Expression of nitric oxide synthase in human central nervous system tumors. Cancer Res 1995; 55: 727-30.
8. Thomsen LL, Lawton FG, Knowles RG et al. Nitric oxide synthase activity in human gynecological cancer. Cancer Res 1994; 54: 1352-4.
9. Thomsen LL, Miles DW, Happerfield L et al. Nitric oxide synthase activity in human breast cancer. Br J Cancer 1995; 72: 41-4.
10. Orucevic A, Bechberger J, Green AM et al. Nitric-oxide production by murine mammary adenocarcinoma cells promotes tumor-cell invasiveness. Int J Cancer 1999; 81: 889-96.
11. Harris SR, Schoeffner DJ, Yoshiji H et al. Tumor growth enhancing effects of vascular endothelial growth factor are associated with increased nitric oxide synthase activity and inhibition of apoptosis in human breast carcinoma xeno-grafts. Cancer Lett 2002; 179: 95-101.
12. Ahmed B, Van Den Oord JJ. Expression of the neuronal isoform of nitric oxide synthase (nNOS) and its inhibitor, protein inhibitor of nNOS, in pigment cell lesions of the skin. Br J Dermatol 1999; 141: 12-9.
13. Massi D, Franchi A, Sardi I et al. Inducible nitric oxide synthase expression in benign and malignant cutaneous melanocytic lesions. J Pathol 2001; 194: 194-200.
14. Tao J, Tu YT. Expression of endothelial nitric oxide syn-thase and vascular endothelial growth factor in human malignant melanoma and their relation to angiogenesis. Chinese J Dermatol 2004; 37: 575-7.
15. Van der Zee R, Murohara T, Luo Z et al. Vascular endothelial growth factor/vascular permeability factor augments nitric oxide release from quiescent rabbit and human vascular endothelium. Circulation 1997; 95: 1030-7.
16. Morbidelli L, Chang CH, Douglas JG et al. Nitric oxide mediates mitogenic effect of VEGF on coronary venular endothelium. Am J Physiol 1996; 270: H411-5.
17. Pricop L, Redecha P, Teillaud J. Differential Modulation of stimulatory and inhibitory Fcc receptors on human monocytes by Th1 and Th2 cytokines. J Immunol 2001; 166: 531-7.
18. Anan K, Morisaki T, Katano M et al. Vascular endothelial growth factor and platelet-derived growth factor are potential angiogenic and metastatic factors in human breast cancer Surgery 1996; 119: 333-9.
19. Hofmann UB, Westphal JR, Wass ET et al. Matrix metal-loproteinnases in human melanoma cell lines and xenografts: increased expression of activated matrix metalloproteinase-2 (MMP-2) correlates with melanoma progression. Br J Cancer 1999; 81: 774-82.
20. Salvucci O, Carsana M, Bersani I et al. Antiapoptotic role of endogenous nitric oxide in human melanoma cells. Cancer Res 2001; 61: 318-26.
21. Ekmekcioglu S, Ellerhorst J, Smid CM et al. Inducible nitric oxide synthase and nitrotyrosine in human metastatic melanoma tumors correlate with poor survival. Clin Cancer Res 2000; 6: 4768-75.
22. Xie K, Huang S, Dong Z et al. Transfection with the indu-cible nitric oxide synthase gene suppresses tumorigenicity and abrogates metastasis by K-1735 murine melanoma cells. J Exp Med 1995; 181: 1333-43.